Home → E-shop → Nucleotides → Entecavir monophosphate – CAS 1103994-53-1

Entecavir monophosphate – CAS 1103994-53-1

Entecavir monophosphate – CAS 1103994-53-1 is synthesized by Sigut Labs (Prague, Czech Republic).

Purity (LC-MS)

min 95%

Package contents

Entecavir monophosphate triethylammonium salt

This compound is for research use only. We do not sell to patients.

Amount

1 mg	€ 3500	Stock
5 mg	€ 8000	Stock
Do you want custom amount?			Custom amount

Amount

1 mg

€ 3500

Stock

5 mg

€ 8000

Stock

Do you want custom amount?

Custom amount

Characterisation

CAS: 1103994-53-1

IUPAC name: 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1H-purin-6-one dihydrogen phosphate

Other names: ETV MP, Baraclude monophosphate

Molecular weight: 357.26 g/mol

Molecular formula: C₁₂H₁₆N₅O₆P

InChI: InChI=1S/C12H16N5O6P/c1-5-6(3-23-24(20,21)22)8(18)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)19/h4,6-8,18H,1-3H2,(H2,20,21,22)(H3,13,15,16,19)/t6-,7-,8-/m0/s1

Description

Entecavir monophosphate is a metabolite of Entacavit. Entecavir is a potent and selective hepatitis B virus reverse transcriptase inhibitor (EC₅₀ = 3 nM); guanine analog. Inhibits hepatitis B virus replication in HepG2.2.15 cells. Displays selectively over HCMV, HSV-1, VZV, HIV and influenza (EC₅₀ values are 15, 32, 30-60, >10 and >80 μM respectively). Orally bioavailable.

Chemicals are distributed worldwide

Buy Entecavir monophosphate now, and get your order in 48 hours

Shipping through DHL in 48 hours
Sensitive compounds are shipped on dry ice
All compounds are safely and rigorously packed

Payment

Payment terms 30 days net
We are sending the invoice the same day as the shipment
We are able to modify the invoice for the academic institution, so the order can be paid from grants

References

Honkoop, P., & De Man, R. A. (2003). Entecavir: a potent new antiviral drug for hepatitis B. Expert opinion on investigational drugs, 12(4), 683-688.
Shaw, T., & Locarnini, S. (2004). Entecavir for the treatment of chronic hepatitis B. Expert review of anti-infective therapy, 2(6), 853-871.
Zoulim, F. (2006). Entecavir: a new treatment option for chronic hepatitis B. Journal of clinical virology, 36(1), 8-12.